Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies

By: Benzinga via Benzinga

March 04, 2016 at 07:11 AM EST

Novo Nordisk (NYSE: NVO) today announced the top-line results from the LEADERtrial, which investigated the cardiovascular safety of ...

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria​; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies​

Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies